GetTopicDetailResponse(id=61184e830e6, topicName=嵌合抗原受體T細胞療法, introduction=嵌合抗原受體T細胞療法, content=null, image=null, comments=3, allHits=1299, url=https://h5.medsci.cn/topic?id=47830, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=88289, tagList=[TagDto(tagId=88289, tagName=嵌合抗原受體T細胞療法)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1709339, encodeId=ff1a1e0933949, content=<a href='/topic/show?id=61184e830e6' target=_blank style='color:#2F92EE;'>#嵌合抗原受體T細胞療法#</a>, objectTitle=Lancet oncol：Axicabtagene ciloleucel（自體抗CD19嵌合抗原受體T細胞療法）治療復發(fā)性/難治性大B細胞淋巴瘤的長期安全性和療, objectType=article, longId=155389, objectId=074b15538986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b15538986, replyNumber=0, likeNumber=109, createdTime=2019-01-16, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b15538986, moduleTitle=Lancet oncol：Axicabtagene ciloleucel（自體抗CD19嵌合抗原受體T細胞療法）治療復發(fā)性/難治性大B細胞淋巴瘤的長期安全性和療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=074b15538986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1709340, encodeId=de601e093404f, content=<a href='/topic/show?id=61184e830e6' target=_blank style='color:#2F92EE;'>#嵌合抗原受體T細胞療法#</a>, objectTitle=Blood：嵌合抗原受體T細胞療法的臨床效果、管理和神經(jīng)毒性, objectType=article, longId=163410, objectId=3d86163410a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d86163410a2, replyNumber=0, likeNumber=96, createdTime=2019-05-08, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d86163410a2, moduleTitle=Blood：嵌合抗原受體T細胞療法的臨床效果、管理和神經(jīng)毒性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3d86163410a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1709338, encodeId=1d141e0933885, content=<a href='/topic/show?id=61184e830e6' target=_blank style='color:#2F92EE;'>#嵌合抗原受體T細胞療法#</a>, objectTitle=用于抗癌的嵌合抗原受體T細胞療法目前已經(jīng)進入臨床試驗階段, objectType=article, longId=45685, objectId=ffa745685e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa745685e8, replyNumber=0, likeNumber=95, createdTime=2015-02-28, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa745685e8, moduleTitle=用于抗癌的嵌合抗原受體T細胞療法目前已經(jīng)進入臨床試驗階段, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ffa745685e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
